Participated · Series A · Feb 2026

Prenosis develops AI-powered diagnostic and therapeutic tools that tailor care to each patient’s unique biological profile. Its core Immunix platform aggregates deep biological data to create diagnostics such as the Sepsis ImmunoScore, the first FDA-authorized AI test for sepsis. The company aims to commercialize ImmunoScore while continuing to expand its portfolio of biology-based diagnostics. Plans include deploying the platform in up to 40 academic medical centers to establish a precision-medicine clinical-trial network, enabling rapid recruitment of patients with specific biological signatures. Led by CEO Bobby Reddy, Jr., PhD, Prenosis positions itself at the intersection of data science, biology, and clinical practice to improve outcomes in critical conditions. The new capital will accelerate product rollout and broaden clinical integration efforts, supporting the company’s mission to personalize critical-care medicine.